TABLE 1.
Study and year | Region and study type | Overall no. a | Qualitative and quantitative analyses no. b | Age (year) | Sex (male %) | Adenocarcinoma (%) | ECOG ≤1% | Brain metastasis (%) | EGFR common mutation (exon19 del or exon21 L858R) % | |||||||
30 mg | 40 mg | 30 mg | 40 mg | 30 mg | 40 mg | 30 mg | 40 mg | 30 mg | 40 mg | 30 mg | 40 mg | 30 mg | 40 mg | |||
afatinib only | ||||||||||||||||
Arrieta, 2015 (Arrieta et al., 2015) | Mexico, prospective cohort study | 84 | 39 | 26 | Overall 59.3 ± 1.6 c | Overall 70.2 | NA | Overall 91.7 | NA | NA | ||||||
Halmos, 2019 (Halmos et al., 2019) | Multicenter, prospective cohort study e | 228 | 73 | 73 | — | — | — | — | — | — | — | — | — | — | — | — |
Lim, 2018 (Lim et al., 2018) | Taiwan, retrospective cohort study | 158 | 44 | 114 | 65.8 (34.3–88.1) d | 61.2 (28.1–88.0) d | 28.1 | 41.1 | 100 | 100 | 89.1 | 94.7 | 32.8 | 31.1 | 68.7 | 86.8 |
Tamura, 2019 (Tamura et al., 2019) | Japan, prospective cohort study | 1602 | 70 | 550 | NA | 34.5 | 43.7 | NA | 76.4 | 89.1 | NA | NA | ||||
Tan, 2018 (Tan et al., 2018) | Singapore, prospective cohort study | 125 | 23 | 37 | Overall 62 (26–86) d | Overall 64 | Overall 96.8 | NA | Overall 33.6 | Overall 91.2 | ||||||
Tanaka, 2018 (Tanaka et al., 2018) | Japan, prospective cohort study | 15 | 3 | 6 | Overall 79 (75–87) d | Overall 20 | Overall 100 | Overall 86.7 | NA | Overall 93.4 | ||||||
Wang, 2019 (Wang et al., 2019) | China, retrospective cohort study | 60 | 19 | 41 | 58.1 (44.6–82.7) d | 57.2 (36.2–70.9) d | 47.4 | 51.2 | 100 | 100 | 100 | 100 | 31.6 | 43.9 | 68.4 | 70.7 |
Wei, 2019 (Wei et al., 2019) | Taiwan, retrospective cohort study | 84 | 22 | 62 | 64.4 ± 12.1 c | 58.8 ± 9.7 c | 31.6 | 32.7 | 100 | 100 | 100 | 94.5 | 100 | 100 | 68.5 | 89.1 |
Yang, 2017 (Yang et al., 2017) | Taiwan, retrospective cohort study | 48 | 29 | 19 | 67.3 ± 8.0 c | 60.6 ± 8.8 c | 21 | 63 | 100 | 100 | 76 | 84 | 28 | 21 | 100 | 100 |
afatinib + 15 mg/ kg bevacizumab | ||||||||||||||||
Ko, 2021 (Ko et al., 2021) | Japan, prospective cohort study | 16 | 14 | 2 | Overall 63 (44–73) d | Overall 31.25 | Overall 100 | Overall 100 | NA | Overall 100 | ||||||
Ninomiya, 2018 (Ninomiya et al., 2018) | Japan, prospective cohort study | 19 | 14 | 5 | 67.5 (40–76) d | 65.0 (42–68) d | 50 | 60 | 100 | 100 | 100 | 100 | 50 | 40 | 100 | 100 |
afatinib +1 mg sirolimus | ||||||||||||||||
Moran, 2017 (Moran et al., 2017) | Spain, prospective cohort study | 39 | 12 | 4 | Overall 58.9 ± 12.3 c | Overall 38.5 | Overall 84.6 | Overall 97.4 | NA | NA |
Total number of people involved in the study, including dose groups other than 30 mg or 40 mg.
Number of people included in the systematic review.
Mean ± standard deviation.
Median (range).
Before and after self-control study.
NA, Not available.